Back to search results

A Study of Eltrekibart and Mirikizumab for Ulcerative Colitis

This study is looking for adults aged 18 to 75 with moderately to severely active ulcerative colitis (UC). You might be able to join if your UC hasn't responded well to other treatments. The study will test two medications, Eltrekibart and Mirikizumab, against a placebo (an inactive substance) to see how safe and effective they are. The main goal is to see what percentage of participants achieve clinical remission (a period where symptoms are greatly reduced or absent) after 12 weeks. The study is currently recruiting about 140 participants, but its overall status is unclear.

Study design
This interventional study plans to enroll 140 participants. It will compare Eltrekibart and Mirikizumab to a placebo.
What's involved
You would need to have an initial screening within 35 days before joining. The total time you would be involved in the study is about 69 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 12, but the total study duration for each participant is about 69 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06598943

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Eli Lilly and Company
~143 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:EltrekibartMirikizumabPlacebo

At a glance

Recruiting sites
151 of 207 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants Achieving Clinical Remission
Measured over Week 12

Conditions

Ulcerative Colitis
Ulcerative Colitis Chronic

Explore related trials

Ulcerative Colitis

Where it's being run

207 sites across 35 states
Japan34
Italy19
Poland18
Germany13
Florida12
California9
Spain9
Serbia8

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have had an established diagnosis of UC of ≥3 months in duration before baseline.
Have moderately to severely active UC as assessed by the UC disease activity score.
Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication (including corticosteroids) or one advanced therapy (including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators).
Are on a stable dose of certain oral UC medications (including corticosteroids).
Must meet contraception requirements.

Exclusion

Have received anti-interleukin (IL)-23p19 or anti-IL-12p40 antibodies in the past.
Have experienced a thrombotic event within 24 weeks before baseline.
Have a current diagnosis of Crohn's Disease or certain other inflammatory gastrointestinal diseases.
Have had certain abdominal surgeries within the past 3 months or are likely to require surgery for UC during the study.
Have a history of certain adenomas, dysplasia's, or malignancies.

What this trial measures

  • Percentage of Participants Achieving Clinical RemissionWeek 12

    Percentage of Participants Achieving Clinical Remission